Pharmacy, PBMs & Pricing
Expert articles and analysis related to pharmacy, pbms & pricing.
AI Summary — Last 7 Days
Over the past week, developments in the pharmacy and PBM landscape have centered on CMS’s release of the Contract Year 2027 Final Rule for Medicare Advantage and Part D, which introduces updated rates and payment policies that will directly impact plan design, medication access, and pharmacy reimbursement structures for Medicare populations. Stakeholder tensions are emerging as these payment reforms and ongoing scrutiny of PBM practices intersect with new platforms for medication access, such as Walmart’s expansion of Better Care Services to include GLP-1s through third-party digital health partners, signaling continued market shifts toward consumer-directed, technology-enabled pharmacy models.
Related Articles
Rising Drug Prices Mean Consumers Bear the Cost
Rising Drug Prices Mean Consumers Bear the Cost AHIP
New Bill Seeks to Lower Out-of-Pocket Drug Costs
New Bill Seeks to Lower Out-of-Pocket Drug Costs MedCity News
Will CMS' new BALANCE model make GLP-1s more affordable?
Will CMS' new BALANCE model make GLP-1s more affordable? Advisory Board
Two visions for value – Why GCEA and HEMA clash on drug pricing
That is the title of my latest Perspectives from the Healthcare Economist article published in The Evidence Base this week. Here is the teaser: In this guest column, healthcare economist Jason Shafrin...
change its pharmacy care model
From newsletter: The LI Daily: Ascendiun CEO Paul Markovich wants the industry to back a policy reform movement focused on affordability, tech innovation Ascendiun CEO Paul Markovich wants the indus...
Today’s Hearing: Drugmakers Want a Blank Check to Keep Overcharging Americans
Today’s Hearing: Drugmakers Want a Blank Check to Keep Overcharging Americans AHIP
Rising Specialty Drug Costs and Co-Pay Models Raise Access Concerns: Patty Taddei-Allen, PharmD, MBA
The AbbVie 340B Lawsuit Signals a Shift from Access to Definition
A recent federal lawsuit filed by AbbVie may prove to be one of the most consequential developments in the evolution of the 340B Drug Pricing Program. While much of the past decade has focused on acce...
STAT+: Maryland state affordability board sets its first price cap for a medicine
The board will now oversee a process to lower the cost of the type 2 diabetes medicine Jardiance by January 2027.
CMS Proposes Reforms to Speed Patient Access to Drugs
CMS Proposes Reforms to Speed Patient Access to Drugs HCI Innovation Group